PolyPid Ltd. unveiled its long-acting GLP-1 receptor agonists delivery platform on July 15, 2025, targeting the diabetes and weight loss market. This proprietary technology aims to subcutaneously deliver GLP-1 for approximately 60 days with a single administration.
This extended delivery period significantly surpasses the current standard of weekly injections, potentially improving patient compliance and therapeutic outcomes. The platform is designed to release GLP-1 linearly, avoiding the burst release issues observed with existing weekly delivered molecules.
The diabetes and weight loss market is projected to reach $100 billion by 2030, representing a substantial opportunity for PolyPid. The company's underlying PLEX technology has been clinically validated in over 1,000 patients, including two Phase 3 trials, with no major safety concerns.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.